Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 181

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Alva, Ajjai S., Mangat, Pam K., Garrett-Mayer, Elizabeth, Halabi, Susan, Hansra, Damien, Calfa, Carmen J., Khalil, Maged F., Ahn, Eugene R., Cannon, Timothy L., Crilley, Pamela, Fisher, Julie G., Haslem, Derrick S., Shrestha, Sagun, Antonelli, Kaitlyn R., Butler, Nicole L., Warren, Sasha L., Rygiel, Andrew L., Ranasinghe, Shamika, Bruinooge, Suanna S., Schilsky, Richard L. · 2021 · Journal of Clinical Oncology

Abstract

PURPOSE: The TAPUR Study is a phase II basket trial that aims to identify signals of antitumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known to be drug targets. Results in a cohort of patients with metastatic breast cancer (mBC) with high tumor mutational burden (HTMB) treated with pembrolizumab are reported. METHODS: Patients with advanced mBC received standard doses of either 2 mg/kg or 200 mg infusions of pembrolizumab every 3 weeks. Simon's two-stage design was used with a primary study end point of disease control (DC) defined as objective response or stable disease of at least 16 weeks duration. If two or more patients in stage I achieved DC, the cohort would enroll 18 additional patients in stage II. Secondary end points include progression-free survival (PFS), overall survival, and safety. RESULTS: Twenty-eight patients were enrolled from October 2016 to July 2018. All patients' tumors had HTMB ranging from 9 to 37 mutations/megabase. DC and objective response were noted in 37% (95% CI, 21 to 50) and 21% of patients (95% CI, 8 to 41), respectively. Median PFS was 10.6 weeks (95% CI, 7.7 to 21.1); median overall survival was 30.6 weeks (95% CI, 18.3 to 103.3). No relationship was observed between PFS and tumor mutational burden. Five patients experienced ≥ 1 serious adverse event or grade 3 adverse event at least possibly related to pembrolizumab consistent with the product label. CONCLUSION: Pembrolizumab monotherapy has antitumor activity in heavily pretreated patients with mBC characterized by HTMB. Our findings support the recent US Food and Drug Administration approval of pembrolizumab for treatment of patients with unresectable or metastatic solid tumors with HTMB without alternative treatment options.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.20.02923

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 181

Metadata

Authors
Alva, A. S., Mangat, P. K., Garrett-Mayer, E., Halabi, S., Hansra, D., Calfa, C. J., Khalil, M. F., Ahn, E. R., Cannon, T. L., Crilley, P., Fisher, J. G., Haslem, D. S., Shrestha, S., Antonelli, K. R., Butler, N. L., Warren, S. L., Rygiel, A. L., Ranasinghe, S., Bruinooge, S. S., & Schilsky, R. L.
Venue
Journal of Clinical Oncology
Published
2021-08-01
Volume
39
Issue
22
Pages
2443-2451
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3152698713
Cited by
181
References
10
FWCI
10.93
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. https://app.cochat.ai/papers/10.1200/jco.20.02923
The paper
Alva, A. S., Mangat, P. K., Garrett-Mayer, E., Halabi, S., Hansra, D., Calfa, C. J., Khalil, M. F., Ahn, E. R., Cannon, T. L., Crilley, P., Fisher, J. G., Haslem, D. S., Shrestha, S., Antonelli, K. R., Butler, N. L., Warren, S. L., Rygiel, A. L., Ranasinghe, S., Bruinooge, S. S., & Schilsky, R. L. (2021). Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.20.02923

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.